Brimonidine/brinzolamide - Alcon

Drug Profile

Brimonidine/brinzolamide - Alcon

Alternative Names: AL-4862/AL-8923A; AL-8923A/AL-4862; Brinzolamide/brimonidine; Simbrinza

Latest Information Update: 13 Dec 2016

Price : $50

At a glance

  • Originator Alcon
  • Class Antiglaucomas; Antihypertensives; Quinoxalines; Sulfonamides; Thiazines
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Carbonic anhydrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension

Most Recent Events

  • 01 Nov 2016 Alcon Research completes a phase III trial in Glaucoma (In adolescents, In adults, In the elderly) in China (Ophthalmic) (NCT02339584)
  • 01 Apr 2015 Phase-III clinical trials in Glaucoma (In adolescents, In adults, In the elderly) in China (Ophthalmic) (NCT02339584)
  • 01 Apr 2015 Phase-III clinical trials in Ocular hypertension (In adolescents, In the elderly, In adults) in China (Ophthalmic) (NCT02339584)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top